Robert J Deans Net Worth

The estimated Net Worth of Robert J Deans is at least $111 Тысяча dollars as of 17 June 2015. Robert Deans owns over 5,080 units of Athersys Inc stock worth over $38,889 and over the last 15 years Robert sold ATHX stock worth over $72,288.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Robert Deans ATHX stock SEC Form 4 insiders trading

Robert has made over 9 trades of the Athersys Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Robert sold 5,080 units of ATHX stock worth $6,248 on 17 June 2015.

The largest trade Robert's ever made was selling 5,080 units of Athersys Inc stock on 17 June 2015 worth over $6,248. On average, Robert trades about 3,076 units every 80 days since 2009. As of 17 June 2015 Robert still owns at least 382,015 units of Athersys Inc stock.

You can see the complete history of Robert Deans stock trades at the bottom of the page.

Insiders trading at Athersys Inc

Over the last 17 years, insiders at Athersys Inc have traded over $3,715,462 worth of Athersys Inc stock and bought 2,242,389 units worth $3,620,264 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Michael B Sheffery и Jordan Davis. On average, Athersys Inc executives and independent directors trade stock every 43 days with the average trade being worth of $3,231. The most recent stock trade was executed by Daniel A. Camardo on 22 November 2022, trading 100,000 units of ATHX stock currently worth $55,000.

What does Athersys Inc do?

athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases. we are engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas. this pipeline includes both stem cell therapy and pharmaceuticals.

Complete history of Robert Deans stock trades at Athersys Inc

Athersys Inc executives and stock owners

Athersys Inc executives and other stock owners filed with the SEC include:

• Gil Van Bokkelen,
  Chairman of the Board, Chief Executive Officer
• John Harrington,
  Executive Vice President, Chief Scientific Officer, Director
• William Lehmann,
  President, Chief Operating Officer
• Laura Campbell,
  Senior Vice President - Finance
• Ivor Macleod CPA, M.B.A.,
  Chief Financial Officer & Principal Accounting Officer
• Dr. John J. Harrington,
  Co-Founder, Chief Scientific Officer, Exec. VP & Director
• William B. J. Lehmann Jr., M.B.A., J.D., MBA,
  Pres, COO, Sec. & Interim CEO
• Lorin Randall,
  Independent Director
• Jack Wyszomierski,
  Independent Director
• Ismail Kola,
  Independent Director
• Jane Wasman,
  Director
• Baiju Shah,
  Director
• Katherine Kalin,
  Director
• Hardy Kagimoto,
  Director
• Maia Hansen,
  Senior Vice President - Operations, Supply Chain
• Ivor Macleod,
  Chief Financial Officer
• Dr. Eric Jenkins M.D.,
  Sr. Medical Director & Head of Clinical Operations
• Maia Hansen M.B.A., M.S.,
  Sr. VP and Head of Operations & Supply Chain
• Rakesh Ramachandran,
  Head of Information Technology & Communications and VP
• Dr. Robert Mays Ph.D.,
  VP of Regenerative Medicine & Head of Neuroscience Programs
• Dr. Manal Morsy M.D., PH.D.,
  Sr. VP & Head of Global Regulatory Affairs
• Alison O'Sullivan M.B.A.,
  Sr. Director of HR
• Karen Hunady M.S.,
  Director of Corp. Communications & Investor Relations
• Jordan Davis,
  Director
• Lee Babiss,
  Director
• Neema Mayhugh,
  Director
• Joseph Patrick Nolan,
  Director
• K.K. Healios,
  
• Tadahisa Kagimoto,
  Director
• Robert J Deans,
  Sr. Vice President
• Kenneth Traub,
  Director
• Advisors Llc Orbi Med Capit...,
  
• George M Jr Milne,
  Director
• Floyd D Md Loop,
  Director
• Advisors Llcisaly Samuel D ...,
  
• Michael B Sheffery,
  Director
• William C Mulligan,
  Director
• Daniel A. Camardo,
  CEO